V
Virginie Bernard
Researcher at Curie Institute
Publications - 41
Citations - 3127
Virginie Bernard is an academic researcher from Curie Institute. The author has contributed to research in topics: Anaplastic lymphoma kinase & Targeted therapy. The author has an hindex of 22, co-authored 40 publications receiving 2510 citations. Previous affiliations of Virginie Bernard include French Institute of Health and Medical Research & PSL Research University.
Papers
More filters
Journal ArticleDOI
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau,Christophe Le Tourneau,Jean Pierre Delord,Anthony Gonçalves,Céline Gavoille,Coraline Dubot,Nicolas Isambert,Mario Campone,Ol vier Trédan,Marie Ange Massiani,Cecile Mauborgne,Sebastien Armanet,Nicolas Servant,Ivan Bièche,Virginie Bernard,David Gentien,Pascal Jézéquel,Valéry Attignon,Sandrine Boyault,Anne Vincent-Salomon,Vincent Servois,Marie Paule Sablin,Maud Kamal,Xavier Paoletti,Xavier Paoletti +24 more
TL;DR: The efficacy of several molecularly targeted agents marketed in France, which were chosen on the basis of tumour molecular profiling but used outside their indications, in patients with advanced cancer for whom standard-of-care therapy had failed is assessed.
Journal ArticleDOI
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld,Derek A. Oldridge,Virginie Bernard,Jan Koster,Leo Colmet Daage,Sharon J. Diskin,Linda Schild,Nadia Bessoltane Bentahar,Angela Bellini,Mathieu Chicard,Eve Lapouble,Valérie Combaret,Patricia Legoix-Né,Jean Michon,Trevor J. Pugh,Lori S. Hart,JulieAnn Rader,Edward F. Attiyeh,Jun S. Wei,Shile Zhang,Arlene Naranjo,Julie M. Gastier-Foster,Michael D. Hogarty,Shahab Asgharzadeh,Malcolm A. Smith,Jaime M. Guidry Auvil,Thomas B.K. Watkins,Danny A. Zwijnenburg,Marli E. Ebus,Peter van Sluis,Anne Hakkert,Esther M. van Wezel,C. Ellen van der Schoot,Ellen M. Westerhout,Johannes H. Schulte,Godelieve A.M. Tytgat,M. Emmy M. Dolman,Isabelle Janoueix-Lerosey,Daniela S Gerhard,Huib N. Caron,Olivier Delattre,Javed Khan,Rogier Versteeg,Gudrun Schleiermacher,Jan J. Molenaar,John M. Maris +45 more
TL;DR: It is shown that RAS-MAPK pathway mutations may function as a biomarker for new therapeutic approaches to refractory disease and provide a rationale for genetic characterization of relapse neuroblastomas.
Journal ArticleDOI
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types
Ronald Lebofsky,Charles Decraene,Virginie Bernard,Maud Kamal,Anthony Blin,Quentin Leroy,Thomas Rio Frio,Gaëlle Pierron,Céline Callens,Ivan Bièche,Adrien Saliou,Jordan Madic,Etienne Rouleau,François-Clément Bidard,Olivier Lantz,Marc-Henri Stern,Christophe Le Tourneau,Jean-Yves Pierga,Jean-Yves Pierga +18 more
TL;DR: Cell‐free tumor DNA analysis is a potential alternative and/or replacement to analyses using costly, harmful and lengthy tissue biopsies of metastasis, irrespective of cancer type and metastatic site, for multiplexed mutation detection in selecting personalized therapies based on the patient's tumor genetic content.
Journal ArticleDOI
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Gudrun Schleiermacher,Niloufar Javanmardi,Virginie Bernard,Quentin Leroy,Julie Cappo,Thomas Rio Frio,Gaëlle Pierron,Eve Lapouble,Valérie Combaret,Franki Speleman,Bram De Wilde,Anna Djos,Ingrid Øra,Fredrik Hedborg,Catarina Träger,Britt-Marie Holmqvist,Jonas Abrahamsson,Michel Peuchmaur,Jean Michon,Isabelle Janoueix-Lerosey,Per Kogner,Olivier Delattre,Tommy Martinsson +22 more
TL;DR: In neuroblastoma, subclonal ALK mutations can be present at diagnosis with subsequent clonal expansion at relapse, highlighting the potential of deep sequencing for detection of sub clonal mutations with a sensitivity 100-fold that of Sanger sequencing and the importance of serial samplings for therapeutic decisions.
Journal ArticleDOI
Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite
Thomas G. P. Grunewald,Thomas G. P. Grunewald,Thomas G. P. Grunewald,Virginie Bernard,Pascale Gilardi-Hebenstreit,Virginie Raynal,Virginie Raynal,Didier Surdez,Didier Surdez,Marie-Ming Aynaud,Marie-Ming Aynaud,Olivier Mirabeau,Olivier Mirabeau,Florencia Cidre-Aranaz,Franck Tirode,Franck Tirode,Sakina Zaidi,Sakina Zaidi,Gaëlle Pérot,Anneliene H. Jonker,Anneliene H. Jonker,Carlo Lucchesi,Carlo Lucchesi,Marie-Cécile Le Deley,Odile Oberlin,Perrine Marec-Berard,Amelie S. Veron,Stéphanie Reynaud,Eve Lapouble,Valentina Boeva,Valentina Boeva,Thomas Rio Frio,Javier Alonso,Smita Bhatia,Gaëlle Pierron,Geraldine Cancel-Tassin,Olivier Cussenot,David G. Cox,Lindsay M. Morton,Mitchell J. Machiela,Stephen J. Chanock,Patrick Charnay,Olivier Delattre +42 more
TL;DR: These findings establish cooperation between a dominant oncogene and a susceptibility variant that regulates a major driver of Ewing sarcomagenesis.